LexDanaLexDanabeta
Inventor

NATASJA BROOIJMANS

Inventor
US

Overview

7→
Patents
2023–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 7 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C07DHeterocyclic compounds27%
C07BGeneral methods of organic chemistry19%
PatentTitleYear
12,595,265Inhibitors of activin receptor-like kinase202612,545,684CDK2 inhibitors202612,172,983EGFR inhibitors202411,970,498CDK2 inhibitors202411,932,648CDK2 inhibitors202411,718,602EGFR inhibitors202311,634,422Inhibitors of activin receptor-like kinase2023

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2023–2026Patents assigned to BLUEPRINT MEDICINES CORP (7)· patent assignee history
2023–2026Based in US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BLUEPRINT MEDICINES CORP72023–2026
Locations
LocationPatentsSpan
US72023–2026